{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:41:10Z","timestamp":1792453270610,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-15202-w","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:35:38Z","timestamp":1784712938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research engagement of rare disease patient advocacy groups in Poland: between participation and constrained co-production"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9710-832X","authenticated-orcid":false,"given":"Jan","family":"Domaradzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8874-2401","authenticated-orcid":false,"given":"Dariusz","family":"Walkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"15202_CR1","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2214-109X(24)00056-1","volume":"12","author":"The Lancet Global Health null","year":"2024","unstructured":"The Lancet Global Health null. The landscape for rare diseases in 2024. Lancet Glob Health. 2024;12:e341. https:\/\/doi.org\/10.1016\/S2214-109X(24)00056-1.","journal-title":"Lancet Glob Health"},{"key":"15202_CR2","doi-asserted-by":"publisher","DOI":"10.2861\/2994008","volume-title":"EU rare disease action plan","author":"European Parliament","year":"2026","unstructured":"European Parliament. Directorate-General for Parliamentary Research Services. In: Dates M, Voarino L, De Weert M, Kazlauskait\u0117 D, Reyniers P, editors. EU rare disease action plan. BE: European Parliament; 2026. https:\/\/doi.org\/10.2861\/2994008."},{"key":"15202_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","volume":"19","author":"M Haendel","year":"2020","unstructured":"Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19:77\u20138. https:\/\/doi.org\/10.1038\/d41573-019-00180-y.","journal-title":"Nat Rev Drug Discov"},{"key":"15202_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165\u201373. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"key":"15202_CR5","doi-asserted-by":"publisher","unstructured":"Smith CIE, Bergman P, Hagey DW. Estimating the number of diseases \u2013 the concept of rare, ultra-rare, and hyper-rare. iScience. 2022;25. https:\/\/doi.org\/10.1016\/j.isci.2022.104698.","DOI":"10.1016\/j.isci.2022.104698"},{"key":"15202_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13023-021-01907-0","volume":"16","author":"F Gorini","year":"2021","unstructured":"Gorini F, Coi A, Mezzasalma L, Baldacci S, Pierini A, Santoro M. Survival of patients with rare diseases: a population-based study in Tuscany (Italy). Orphanet J Rare Dis. 2021;16:275. https:\/\/doi.org\/10.1186\/s13023-021-01907-0.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13073-022-01026-w","volume":"14","author":"S Marwaha","year":"2022","unstructured":"Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022;14:23. https:\/\/doi.org\/10.1186\/s13073-022-01026-w.","journal-title":"Genome Med"},{"key":"15202_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-018-0294-9","author":"J Baumbusch","year":"2018","unstructured":"Baumbusch J, Mayer S, Sloan-Yip I. Alone in a Crowd? Parents of Children with Rare Diseases\u2019 Experiences of Navigating the Healthcare System. J Genet Couns. 2018. https:\/\/doi.org\/10.1007\/s10897-018-0294-9.","journal-title":"J Genet Couns"},{"key":"15202_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cch.12628","volume":"45","author":"G Currie","year":"2019","unstructured":"Currie G, Szabo J. It is like a jungle gym, and everything is under construction: The parent\u2019s perspective of caring for a child with a rare disease. Child Care Health Dev. 2019;45:96\u2013103. https:\/\/doi.org\/10.1111\/cch.12628.","journal-title":"Child Care Health Dev"},{"key":"15202_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/cch.12866","volume":"47","author":"S Aldiss","year":"2021","unstructured":"Aldiss S, Gibson F, Geoghegan S, Jewitt A, Elliott TK, Williams A, et al. We don\u2019t know what tomorrow will bring: Parents\u2019 experiences of caring for a child with an undiagnosed genetic condition. Child Care Health Dev. 2021;47:588\u201396. https:\/\/doi.org\/10.1111\/cch.12866.","journal-title":"Child Care Health Dev"},{"key":"15202_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s13023-021-02127-2","volume":"16","author":"S Witt","year":"2021","unstructured":"Witt S, Kristensen K, Wiegand-Grefe S, Boettcher J, Bloemeke J, Wingartz C, et al. Rare pediatric diseases and pathways to psychosocial care: a qualitative interview study with professional experts working with affected families in Germany. Orphanet J Rare Dis. 2021;16:497. https:\/\/doi.org\/10.1186\/s13023-021-02127-2.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR12","doi-asserted-by":"publisher","first-page":"14016","DOI":"10.1038\/s41598-024-63962-4","volume":"14","author":"J Domaradzki","year":"2024","unstructured":"Domaradzki J, Walkowiak D. Invisible patients in rare diseases: parental experiences with the healthcare and social services for children with rare diseases. A mixed method study. Sci Rep. 2024;14:14016. https:\/\/doi.org\/10.1038\/s41598-024-63962-4.","journal-title":"Sci Rep"},{"key":"15202_CR13","doi-asserted-by":"publisher","first-page":"22678","DOI":"10.1038\/s41598-025-08866-7","volume":"15","author":"J Domaradzki","year":"2025","unstructured":"Domaradzki J, Jabkowski P, Walkowiak D. Rare disease, common struggles: quality of life, caregiver burden and financial wellbeing of family caregivers in Poland. Sci Rep. 2025;15:22678. https:\/\/doi.org\/10.1038\/s41598-025-08866-7.","journal-title":"Sci Rep"},{"key":"15202_CR14","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(08)60872-7","volume":"371","author":"A Schieppati","year":"2008","unstructured":"Schieppati A, Henter J-I, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(08)60872-7.","journal-title":"Lancet"},{"key":"15202_CR15","doi-asserted-by":"publisher","first-page":"1028545","DOI":"10.3389\/fpubh.2022.1028545","volume":"10","author":"CCY Chung","year":"2022","unstructured":"Chung CCY, Chu ATW, Chung BHY. Rare disease emerging as a global public health priority. Front Public Health. 2022;10:1028545. https:\/\/doi.org\/10.3389\/fpubh.2022.1028545.","journal-title":"Front Public Health"},{"key":"15202_CR16","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(24)00134-7","volume":"12","author":"G Baynam","year":"2024","unstructured":"Baynam G, Hartman AL, Letinturier MCV, Bolz-Johnson M, Carrion P, Grady AC, et al. Global health for rare diseases through primary care. Lancet Glob Health. 2024;12:e1192\u20139. https:\/\/doi.org\/10.1016\/S2214-109X(24)00134-7.","journal-title":"Lancet Glob Health"},{"key":"15202_CR17","doi-asserted-by":"publisher","first-page":"1706653","DOI":"10.3389\/fpubh.2025.1706653","volume":"13","author":"M Junaid","year":"2025","unstructured":"Junaid M, Downs J, Groza T, Lassmann T, Baker S, Stevens K, et al. The United Nations convention on rare diseases-A framework for research prioritization. Front Public Health. 2025;13:1706653. https:\/\/doi.org\/10.3389\/fpubh.2025.1706653.","journal-title":"Front Public Health"},{"key":"15202_CR18","unstructured":"World Health Assembly Resolution on Rare Diseases. Rare Diseases International. https:\/\/www.rarediseasesinternational.org\/wha-resolution\/. Accessed 28 Mar 2026."},{"key":"15202_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.drudis.2019.01.005","volume":"24","author":"DA Fonseca","year":"2019","unstructured":"Fonseca DA, Amaral I, Pinto AC, Cotrim MD. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today. 2019;24:867\u201372. https:\/\/doi.org\/10.1016\/j.drudis.2019.01.005.","journal-title":"Drug Discov Today"},{"key":"15202_CR20","doi-asserted-by":"publisher","first-page":"102201","DOI":"10.1016\/j.coph.2022.102201","volume":"63","author":"MD Amaral","year":"2022","unstructured":"Amaral MD. Precision medicine for rare diseases: The times they are A-Changin\u2019. Curr Opin Pharmacol. 2022;63:102201. https:\/\/doi.org\/10.1016\/j.coph.2022.102201.","journal-title":"Curr Opin Pharmacol"},{"key":"15202_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","volume":"18","author":"LJ Fermaglich","year":"2023","unstructured":"Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis. 2023;18:163. https:\/\/doi.org\/10.1186\/s13023-023-02790-7.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR22","doi-asserted-by":"publisher","DOI":"10.2174\/0113892010371761250616112614","author":"A Debnath","year":"2025","unstructured":"Debnath A, Mazumder R, Mazumder A, Tyagi PK, Singh RK. Challenges and Progress of Orphan Drug Development for Rare Diseases. Curr Pharm Biotechnol. 2025. https:\/\/doi.org\/10.2174\/0113892010371761250616112614.","journal-title":"Curr Pharm Biotechnol"},{"key":"15202_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13023-024-03146-5","volume":"19","author":"S Mishra","year":"2024","unstructured":"Mishra S, Venkatesh MP. Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges. Orphanet J Rare Dis. 2024;19:285. https:\/\/doi.org\/10.1186\/s13023-024-03146-5.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/978-3-319-67144-4_30","volume-title":"Rare Diseases Epidemiology: Update and Overview","author":"AM Moliner","year":"2017","unstructured":"Moliner AM, Waligora J. The European Union Policy in the Field of Rare Diseases. In: de la Posada M, Taruscio D, Groft SC, editors. Rare Diseases Epidemiology: Update and Overview. Cham: Springer International Publishing; 2017. pp. 561\u201387. https:\/\/doi.org\/10.1007\/978-3-319-67144-4_30."},{"key":"15202_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/gt.2017.29","volume":"24","author":"D Julkowska","year":"2017","unstructured":"Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 2017;24:562\u201371. https:\/\/doi.org\/10.1038\/gt.2017.29.","journal-title":"Gene Ther"},{"key":"15202_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fpubh.2019.00416","volume":"7","author":"M Czech","year":"2019","unstructured":"Czech M, Baran-Kooiker A, Atikeler K, Demirtshyan M, Gaitova K, Holownia-Voloskova M, et al. A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries. Front Public Health. 2019;7:416. https:\/\/doi.org\/10.3389\/fpubh.2019.00416.","journal-title":"Front Public Health"},{"key":"15202_CR27","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/bcp.70013","volume":"91","author":"A Belan\u010di\u0107","year":"2025","unstructured":"Belan\u010di\u0107 A, Gkrinia EMM, Liki\u0107 R, Vitezi\u0107 D. Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases. Br J Clin Pharmacol. 2025;91:1084\u20137. https:\/\/doi.org\/10.1002\/bcp.70013.","journal-title":"Br J Clin Pharmacol"},{"key":"15202_CR28","unstructured":"Orphan medicinal products - Public Health - European Commission. 2026. https:\/\/health.ec.europa.eu\/medicinal-products\/product-types\/orphan-medicinal-products_en. Accessed 28 Apr 2026."},{"key":"15202_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13023-025-03756-7","volume":"20","author":"E Hahl","year":"2025","unstructured":"Hahl E, Kurko T, Koskinen H, Airaksinen M, Sarnola K. EMA approved orphan medicines since the implementation of the orphan legislation. Orphanet J Rare Dis. 2025;20:266. https:\/\/doi.org\/10.1186\/s13023-025-03756-7.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR30","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s43441-025-00810-1","volume":"59","author":"G Santi Laurini","year":"2025","unstructured":"Santi Laurini G, Nikitina V, Broccoli M, Montanaro N, Motola D. Overview of Orphan Medicines in European Union: An Analysis of Regulatory and Technical\u2013Scientific Aspects. Ther Innov Regul Sci. 2025;59:1087\u201397. https:\/\/doi.org\/10.1007\/s43441-025-00810-1.","journal-title":"Ther Innov Regul Sci"},{"key":"15202_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000342758","volume":"3","author":"M Mavris","year":"2012","unstructured":"Mavris M, Le Cam Y. Involvement of patient organisations in research and development of orphan drugs for rare diseases in europe. Mol Syndromol. 2012;3:237\u201343. https:\/\/doi.org\/10.1159\/000342758.","journal-title":"Mol Syndromol"},{"key":"15202_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15265161.2023.2207500","volume":"23","author":"MC Halley","year":"2023","unstructured":"Halley MC, Halverson CME, Tabor HK, Goldenberg AJ. Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care. Am J Bioeth. 2023;23:17\u201326. https:\/\/doi.org\/10.1080\/15265161.2023.2207500.","journal-title":"Am J Bioeth"},{"key":"15202_CR33","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/genes15091162","volume":"15","author":"Y Poortman","year":"2024","unstructured":"Poortman Y, Ens-Dokkum M, Nippert I. The role of patient organizations in shaping research, health policies, and health services for rare genetic diseases: the Dutch experience. Genes (Basel). 2024;15:1162. https:\/\/doi.org\/10.3390\/genes15091162.","journal-title":"Genes (Basel)"},{"key":"15202_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13023-022-02317-6","volume":"17","author":"CQ Nguyen","year":"2022","unstructured":"Nguyen CQ, Alba-Concepcion K, Palmer EE, Scully JL, Millis N, Farrar MA. The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review. Orphanet J Rare Dis. 2022;17:167. https:\/\/doi.org\/10.1186\/s13023-022-02317-6.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13023-024-03262-2","volume":"19","author":"TL Klein","year":"2024","unstructured":"Klein TL, Bender J, Bolton S, Collin-Histed T, Daher A, De Baere L, et al. A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem. Orphanet J Rare Dis. 2024;19:262. https:\/\/doi.org\/10.1186\/s13023-024-03262-2.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR36","doi-asserted-by":"publisher","first-page":"e039473","DOI":"10.1136\/bmjopen-2020-039473","volume":"10","author":"A Roennow","year":"2020","unstructured":"Roennow A, Sauv\u00e9 M, Welling J, Riggs RJ, Kennedy AT, Galetti I, et al. Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations. BMJ Open. 2020;10:e039473. https:\/\/doi.org\/10.1136\/bmjopen-2020-039473.","journal-title":"BMJ Open"},{"key":"15202_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40900-024-00609-8","volume":"10","author":"A Janssens","year":"2024","unstructured":"Janssens A, Drachmann D, Barnes-Cullen K, Carrigg A, Christesen HT, Futers B, et al. An auto-ethnographic study of co-produced health research in a patient organisation: unpacking the good, the bad, and the unspoken. Res Involv Engagem. 2024;10:76. https:\/\/doi.org\/10.1186\/s40900-024-00609-8.","journal-title":"Res Involv Engagem"},{"key":"15202_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13023-016-0445-8","volume":"11","author":"PA Merkel","year":"2016","unstructured":"Merkel PA, Manion M, Gopal-Srivastava R, Groft S, Jinnah HA, Robertson D, et al. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis. 2016;11:66. https:\/\/doi.org\/10.1186\/s13023-016-0445-8.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0382-6","volume":"11","author":"D Pinto","year":"2016","unstructured":"Pinto D, Martin D, Chenhall R. The involvement of patient organisations in rare disease research: a mixed methods study in Australia. Orphanet J Rare Dis. 2016;11:2. https:\/\/doi.org\/10.1186\/s13023-016-0382-6.","journal-title":"Orphanet J Rare Dis"},{"key":"15202_CR40","doi-asserted-by":"publisher","first-page":"jcs264320","DOI":"10.1242\/jcs.264320","volume":"138","author":"T Ogden","year":"2025","unstructured":"Ogden T, de Graaf B, Hymers T. Engaging patient-led rare disease organizations to advance research - through the lens of Bardet-Biedl syndrome. J Cell Sci. 2025;138:jcs264320. https:\/\/doi.org\/10.1242\/jcs.264320.","journal-title":"J Cell Sci"},{"issue":"Suppl 3","key":"15202_CR41","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11606-014-2895-9","volume":"29","author":"LP Forsythe","year":"2014","unstructured":"Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, et al. A Systematic Review of Approaches for Engaging Patients for Research on Rare Diseases. J Gen Intern Med. 2014;29(Suppl 3):788\u2013800. https:\/\/doi.org\/10.1007\/s11606-014-2895-9.","journal-title":"J Gen Intern Med"},{"key":"15202_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/03085140050174750","volume":"29","author":"C Novas","year":"2000","unstructured":"Novas C, Rose N. Genetic risk and the birth of the somatic individual. Econ Soc. 2000;29:485\u2013513. https:\/\/doi.org\/10.1080\/03085140050174750.","journal-title":"Econ Soc"},{"key":"15202_CR43","doi-asserted-by":"publisher","unstructured":"Dong T, Xie D. Exploring the path for patient organizations to participate in medical security for rare diseases. Front Public Health. 2025;13. https:\/\/doi.org\/10.3389\/fpubh.2025.1484286.","DOI":"10.3389\/fpubh.2025.1484286"},{"key":"15202_CR44","doi-asserted-by":"publisher","first-page":"1653304","DOI":"10.3389\/fmed.2025.1653304","volume":"12","author":"S Akodad","year":"2025","unstructured":"Akodad S, De Smedt D, Stevens H. Societal participation in the development of orphan drugs: a systematic review. Front Med (Lausanne). 2025;12:1653304. https:\/\/doi.org\/10.3389\/fmed.2025.1653304.","journal-title":"Front Med (Lausanne)"},{"key":"15202_CR45","doi-asserted-by":"publisher","first-page":"e70524","DOI":"10.1111\/hex.70524","volume":"28","author":"J Frost","year":"2025","unstructured":"Frost J, Widening Engagement Patient Advisory Group, Mandizha J, van den Dungen C, Asare L, Pope C. Can the Development of Orphan Drugs Include Wider Patient Engagement? A Citizens\u2019 Jury to Explore a Promissory Notion. Health Expect. 2025;28:e70524. https:\/\/doi.org\/10.1111\/hex.70524.","journal-title":"Health Expect"},{"key":"15202_CR46","doi-asserted-by":"publisher","unstructured":"Nori M, Fisher-Vance,Dakota, Wuerth, Laura, Colenso, Rob, and, Donovan DJ. The global role of patients, advocates and caregivers in rare diseases. future rare diseases. 2022;2:FRD22. https:\/\/doi.org\/10.2217\/frd-2022-0003.","DOI":"10.2217\/frd-2022-0003"},{"key":"15202_CR47","doi-asserted-by":"publisher","first-page":"116332","DOI":"10.1016\/j.socscimed.2023.116332","volume":"338","author":"A Gentilini","year":"2023","unstructured":"Gentilini A, Miraldo M. The role of patient organisations in research and development: Evidence from rare diseases. Soc Sci Med. 2023;338:116332. https:\/\/doi.org\/10.1016\/j.socscimed.2023.116332.","journal-title":"Soc Sci Med"},{"key":"15202_CR48","unstructured":"Plan dla chor\u00f3b rzadkich | Choroby Rzadkie. https:\/\/chorobyrzadkie.gov.pl\/pl\/choroby-rzadkie\/plan-dla-chorob-rzadkich. Accessed 17 Mar 2026."},{"key":"15202_CR49","unstructured":"Rada Ministr\u00f3w przyj\u0119\u0142a Plan. dla Chor\u00f3b Rzadkich na lata 2024\u20132025 - Ministerstwo Zdrowia - Portal Gov.pl. Ministerstwo Zdrowia. https:\/\/www.gov.pl\/web\/zdrowie\/rada-ministrow-przyjela-plan-dla-chorob-rzadkich-na-lata-2024-2025. Accessed 9 Sept 2024."},{"key":"15202_CR50","doi-asserted-by":"publisher","unstructured":"Domaradzki J. We are ambassadors, we are advocates: rare disease patient advocacy groups as knowledge brokers across health and social systems\u2014a qualitative study from Poland. Front Public Health. 2026;14. https:\/\/doi.org\/10.3389\/fpubh.2026.1743598.","DOI":"10.3389\/fpubh.2026.1743598"},{"key":"15202_CR51","unstructured":"Audyt. 2025 \u2013 Krajowe forum ORPHAN. https:\/\/rzadkiechoroby.org\/audyt\/audyt-2025-2\/. Accessed 4 Nov 2025."},{"key":"15202_CR52","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"key":"15202_CR53","doi-asserted-by":"publisher","unstructured":"Seely EW, Grinspoon S. Chapter 2 - patient-oriented research. In: Robertson D, Williams GH, editors. Clinical and translational science (2nd ed.). Academic Press; 2017. pp. 9\u201323. https:\/\/doi.org\/10.1016\/B978-0-12-802101-9.00002-8.","DOI":"10.1016\/B978-0-12-802101-9.00002-8"},{"key":"15202_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40900-020-0180-0","volume":"6","author":"N Frisch","year":"2020","unstructured":"Frisch N, Atherton P, Doyle-Waters MM, MacLeod MLP, Mallidou A, Sheane V, et al. Patient-oriented research competencies in health (PORCH) for researchers, patients, healthcare providers, and decision-makers: results of a scoping review. Res Involv Engagem. 2020;6:4. https:\/\/doi.org\/10.1186\/s40900-020-0180-0.","journal-title":"Res Involv Engagem"},{"key":"15202_CR55","doi-asserted-by":"publisher","first-page":"e700","DOI":"10.20883\/medical.e700","volume":"91","author":"N Sawicka-Gutaj","year":"2022","unstructured":"Sawicka-Gutaj N, Gruszczy\u0144ski D, Guzik P, Mostowska A, Walkowiak J. Publication ethics of human studies in the light of the Declaration of Helsinki \u2013 a mini-review. JMS. 2022;91:e700. https:\/\/doi.org\/10.20883\/medical.e700.","journal-title":"JMS"},{"key":"15202_CR56","doi-asserted-by":"publisher","first-page":"263300402311644","DOI":"10.1177\/26330040231164425","volume":"4","author":"AM Patterson","year":"2023","unstructured":"Patterson AM, O\u2019Boyle M, VanNoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. Ther Adv Rare Dis. 2023;4:26330040231164425. https:\/\/doi.org\/10.1177\/26330040231164425.","journal-title":"Ther Adv Rare Dis"},{"key":"15202_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1472-6963-14-89","volume":"14","author":"JP Domecq","year":"2014","unstructured":"Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N, et al. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14:89. https:\/\/doi.org\/10.1186\/1472-6963-14-89.","journal-title":"BMC Health Serv Res"},{"key":"15202_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s43856-023-00251-7","volume":"3","author":"Patient engagement and involvement in rare disease research","year":"2023","unstructured":"Patient engagement and involvement in rare disease research. Commun Med. 2023;3:20. https:\/\/doi.org\/10.1038\/s43856-023-00251-7.","journal-title":"Commun Med"},{"key":"15202_CR59","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.88630","author":"Y Bhattacharya","year":"2019","unstructured":"Bhattacharya Y, Iyer G, Kamireddy AP, Poornima S, Juturu KK, Hasan Q, et al. Rare Disease Advocacy Groups and Their Significance in Diagnosis, Management, Treatment, and Prevention of Rare Diseases. Rare Dis. 2019. https:\/\/doi.org\/10.5772\/intechopen.88630. IntechOpen.","journal-title":"Rare Dis"},{"key":"15202_CR60","doi-asserted-by":"publisher","first-page":"117958","DOI":"10.1016\/j.socscimed.2025.117958","volume":"372","author":"R Dimond","year":"2025","unstructured":"Dimond R, Lewis J. My full-time unpaid role: Understanding the (extra)ordinary work of founders of rare disease organisations. Soc Sci Med. 2025;372:117958. https:\/\/doi.org\/10.1016\/j.socscimed.2025.117958.","journal-title":"Soc Sci Med"},{"key":"15202_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jmd2.12403","volume":"65","author":"N Awada","year":"2024","unstructured":"Awada N, Holcik M. Patient and family experiences of lysosomal storage diseases in Canada: A qualitative interview study. JIMD Rep. 2024;65:63\u201384. https:\/\/doi.org\/10.1002\/jmd2.12403.","journal-title":"JIMD Rep"},{"key":"15202_CR62","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/jlme.12078","volume":"41","author":"SL Rose","year":"2013","unstructured":"Rose SL. Patient Advocacy Organizations: Institutional Conflicts of Interest, Trust, and Trustworthiness. J Law Med Ethics. 2013;41:680\u20137. https:\/\/doi.org\/10.1111\/jlme.12078.","journal-title":"J Law Med Ethics"},{"key":"15202_CR63","unstructured":"The third wave of science studies, - HM, Collins R, Evans. 2002. https:\/\/journals.sagepub.com\/doi\/10.1177\/0306312702032002003. Accessed 26 Jan 2026."},{"key":"15202_CR64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/01944366908977225","volume":"35","author":"SR Arnstein","year":"1969","unstructured":"Arnstein SR. A Ladder Of Citizen Participation. J Am Inst Planners. 1969;35:216\u201324. https:\/\/doi.org\/10.1080\/01944366908977225.","journal-title":"J Am Inst Planners"},{"key":"15202_CR65","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/fampra\/cmw097","volume":"34","author":"DL Hahn","year":"2017","unstructured":"Hahn DL, Hoffmann AE, Felzien M, LeMaster JW, Xu J, Fagnan LJ. Tokenism in patient engagement. Fam Pract. 2017;34:290\u20135. https:\/\/doi.org\/10.1093\/fampra\/cmw097.","journal-title":"Fam Pract"},{"key":"15202_CR66","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/ageing\/afm029","volume":"36","author":"N Fudge","year":"2007","unstructured":"Fudge N, Wolfe CDA, McKevitt C. Involving older people in health research. Age Ageing. 2007;36:492\u2013500. https:\/\/doi.org\/10.1093\/ageing\/afm029.","journal-title":"Age Ageing"},{"key":"15202_CR67","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.2217\/fon-2021-0556","volume":"17","author":"BB Davies-Teye","year":"2021","unstructured":"Davies-Teye BB, Medeiros M, Chauhan C, Baquet CR, Mullins CD. Pragmatic patient engagement in designing pragmatic oncology clinical trials. Future Oncol. 2021;17:3691\u2013704. https:\/\/doi.org\/10.2217\/fon-2021-0556.","journal-title":"Future Oncol"},{"key":"15202_CR68","volume-title":"States of Knowledge: The Co-Production of Science and Social Order","year":"2004","unstructured":"Jasanoff S, editor. States of Knowledge: The Co-Production of Science and Social Order. New York: Routledge; 2004."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15202-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:07:25Z","timestamp":1792451245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15202-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15202"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-15202-w","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethics and research governance approval were obtained from the Bioethics Committee of Poznan University of Medical Sciences (KB-879\/25, granted on 10.12.2025). Informed written consent was obtained from all individual participants in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors used Grammarly and ChatGPT to refine the language editing and grammar improvement. All text was critically reviewed, verified, and edited by the authors, who take full responsibility for the final version of the manuscript.","order":3,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1429"}}